Otsuka Holdings Co., Ltd.: Autistic Disorder trials
The registry lists 11 Autistic Disorder studies with Otsuka Holdings Co., Ltd. as lead sponsor. 0 are open to participants now and 9 have results posted.
Phase 1 1Phase 3 8Phase 4 1No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148CompletedNCT04258839Phase 3Results posted
- Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum DisorderCompletedNCT04174365Phase 3Results posted
- Post-Marketing Surveillance Study of Aripiprazole in Patients With AutismCompletedNCT03179787Results posted
- A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic DisorderCompletedNCT01617460Phase 3Results posted
- A Short Treatment Study of Aripiprazole in Pediatric Patients With Autistic DisorderCompletedNCT01617447Phase 3Results posted
- Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic DisorderCompletedNCT01227668Phase 4Results posted
- Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)CompletedNCT00365859Phase 3Results posted
- Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)CompletedNCT00337571Phase 3Results posted
- Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD).CompletedNCT00332241Phase 3Results posted
- Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Autistic DisorderCompletedNCT03487770Phase 3
- Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System DisordersCompletedNCT03292848Phase 1